Difference between revisions of "Camrelizumab (AiRuiKa)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 17: Line 17:
 
[[Category:Anti-PD-1 antibodies]]
 
[[Category:Anti-PD-1 antibodies]]
  
[[Category:Esophageal cancer medications]]
+
[[Category:Esophageal squamous cancer medications]]
 
[[Category:Nasopharyngeal carcinoma medications]]
 
[[Category:Nasopharyngeal carcinoma medications]]
  
 
[[Category:NMPA approved drugs]]
 
[[Category:NMPA approved drugs]]

Revision as of 02:00, 1 May 2022

Mechanism of action

From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, camrelizumab binds to and blocks the binding of PD-1, expressed on activated T lymphocytes, B cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens.

Toxicity management

Diseases for which it is used

Also known as

  • Code names: HR-301210, SHR-1210
  • Brand name: AiRuiKa